Mobile

An extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013412-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to investigate the long-term safety and tolerability of SIAC. This is done by comparing SIAC to insulin detemir after 52 weeks of treatment (26 weeks of treatment in trial NN5401-3594 plus 26 weeks of treatment in this extension trial) in terms of the following safety assessments from which endpoints will be calculated: • Adverse events • Hypoglycaemic episodes • Clinical evaluations • Central laboratory assessments including lipid profiles and insulin antibodies • Body weight • Insulin dose

Critère d'inclusion

  • Type 1 Diabetes

Liens